Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Assets Average (2021 - 2025)

Bolt Biotherapeutics' Assets Average history spans 5 years, with the latest figure at $70.3 million for Q3 2025.

  • For Q3 2025, Assets Average fell 39.81% year-over-year to $70.3 million; the TTM value through Sep 2025 reached $70.3 million, down 39.81%, while the annual FY2024 figure was $129.7 million, 33.07% down from the prior year.
  • Assets Average for Q3 2025 was $70.3 million at Bolt Biotherapeutics, down from $80.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $340.3 million in Q3 2021 and bottomed at $70.3 million in Q3 2025.
  • The 5-year median for Assets Average is $185.6 million (2021), against an average of $197.6 million.
  • The largest annual shift saw Assets Average soared 59.09% in 2022 before it crashed 39.81% in 2025.
  • A 5-year view of Assets Average shows it stood at $320.6 million in 2021, then dropped by 26.19% to $236.7 million in 2022, then fell by 29.19% to $167.6 million in 2023, then tumbled by 37.65% to $104.5 million in 2024, then plummeted by 32.74% to $70.3 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Assets Average are $70.3 million (Q3 2025), $80.7 million (Q2 2025), and $92.7 million (Q1 2025).